# US 2024/0002950 A1 · Panel of ER Regulated Genes for Use in Monitoring Endocrine Therapy in Breast Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002950 A1
- Document ID: US20240002950A1
- Status: Published application
- Kind: A1
- Application number: 18/253,640
- Filed: 2021-11-22
- Published: 2024-01-04
- Earliest claimed: 2020-11-23
- Assignees: Sanofi
- Applicants: Sanofi
- Inventors: Monsif Bouaboula; Hui Cao; Joon Sang Lee; Vasiliki Pelekanou; Maysoun Shomali
- Web page: https://patentgrep.com/patent/US20240002950A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure relates to a panel of ER regulated genes and method for using the panel for monitoring the response of an individual having cancer to treatment with amcenestrant, the method comprising determining a first ER activity score from a sample from the individual at a first time point before treatment with amcenestrant using the panel, then determining a second ER activity score from a sample from the individual at a second time point following administration of amcenestrant using the panel, and comparing the first ER activity score with the second ER activity score, wherein a decrease in the second ER activity score relative to the first ER activity score is predictive of target engagement of amcenestrant.

## Claims

### Claim 1

A panel of ER regulated genes having N genes, wherein N is at least 7 and equal to or less than about 87, and wherein the N genes comprise any 2 to 21 of the following upregulated genes: PTPRT, CAMK1D, BCAS1, ABCG1, KRT81, TLE2, SALL4, ITGB6, BBC3, IL1R1, CORO2A, GRM4, ATP6V0A4, MATN2, PPFIBP2, BMF, LOC283070, PSCA, BAK1, PLIN2, and SYNPO; and the N genes comprise any 5 to 66 of the following downregulated genes: H19, MYBL1, MGP, SLC5A8, PKIB, PGR, TMPRSS3, IGSF1, COL21A1, FSIP1, KLHL4, EGR3, NPY1R, HIST1H3C, GRIK3, SCNN1B, FRK, PRSS23, SERPINA5, SFXN2, CAP2, HIST1H2BM, CDC45, WDR62, DSCC1, GJA1, FAM196A, NTRK2, RAD54L, SDK2, SLC4A10, HIST1H4D, HIST1H4C, RGS22, SYBU, CA8, DIAPH3, FHL2, HIST1H1B, KCNH1, RAD51AP1, FANCD2, SLC39A8, SKP2, HIST1H3B, TMEM164, AURKB, DEPTOR, XRCC2, C1QTNF6, ERCC6L, ORC1, HIST2H2AC, RRM2, EME1, HIST1H2BF, CLSPN, EXO1, SDC2, HIST1H3I, HIST2H2AB, HIST1H4B, ASCL1, ATAD5, HIST1H1D, and HIST1H2BH.

### Claim 2 (depends on 1)

The panel of claim 1, wherein N is 87, and wherein the 87 genes comprise the following 21 upregulated genes: PTPRT, CAMK1D, BCAS1, ABCG1, KRT81, TLE2, SALL4, ITGB6, BBC3, IL1R1, CORO2A, GRM4, ATP6V0A4, MATN2, PPFIBP2, BMF, LOC283070, PSCA, BAK1, PLIN2, and SYNPO; and the 87 genes comprise the following 66 downregulated genes: H19, MYBL1, MGP, SLC5A8, PKIB, PGR, TMPRSS3, IGSF1, COL21A1, FSIP1, KLHL4, EGR3, NPY1R, HIST1H3C, GRIK3, SCNN1B, FRK, PRSS23, SERPINA5, SFXN2, CAP2, HIST1H2BM, CDC45, WDR62, DSCC1, GJA1, FAM196A, NTRK2, RAD54L, SDK2, SLC4A10, HIST1H4D, HIST1H4C, RGS22, SYBU, CA8, DIAPH3, FHL2, HIST1H1B, KCNH1, RAD51AP1, FANCD2, SLC39A8, SKP2, HIST1H3B, TMEM164, AURKB, DEPTOR, XRCC2, C1QTNF6, ERCC6L, ORC1, HIST2H2AC, RRM2, EME1, HIST1H2BF, CLSPN, EXO1, SDC2, HIST1H3I, HIST2H2AB, HIST1H4B, ASCL1, ATAD5, HIST1H1D, and HIST1H2BH.

### Claim 3

A method for monitoring the response of an individual having cancer to treatment with amcenestrant, the method comprising: (a) determining a first ER activity score from a sample from the individual at a first time point before treatment with amcenestrant; (b) following step (a), determining a second ER activity score from a sample from the individual at a second time point following administration of amcenestrant; and (c) comparing the first ER activity score with the second ER activity score, wherein a decrease in the second ER activity score relative to the first ER activity score is predictive of target engagement of amcenestrant,
wherein determining the first ER activity score and the second ER activity score comprises analyzing a panel of ER regulated genes having N genes, wherein N is at least 7 and equal to or less than 87, and wherein the N genes comprise any 2 to 21 of the following upregulated genes: PTPRT, CAMK1D, BCAS1, ABCG1, KRT81, TLE2, SALL4, ITGB6, BBC3, IL1R1, CORO2A, GRM4, ATP6V0A4, MATN2, PPFIBP2, BMF, LOC283070, PSCA, BAK1, PLIN2, and SYNPO; and the N genes comprise any 5 to 66 of the following downregulated genes: H19, MYBL1, MGP, SLC5A8, PKIB, PGR, TMPRSS3, IGSF1, COL21A1, FSIP1, KLHL4, EGR3, NPY1R, HIST1H3C, GRIK3, SCNN1B, FRK, PRSS23, SERPINA5, SFXN2, CAP2, HIST1H2BM, CDC45, WDR62, DSCC1, GJA1, FAM196A, NTRK2, RAD54L, SDK2, SLC4A10, HIST1H4D, HIST1H4C, RGS22, SYBU, CA8, DIAPH3, FHL2, HIST1H1B, KCNH1, RAD51AP1, FANCD2, SLC39A8, SKP2, HIST1H3B, TMEM164, AURKB, DEPTOR, XRCC2, C1QTNF6, ERCC6L, ORC1, HIST2H2AC, RRM2, EME1, HIST1H2BF, CLSPN, EXO1, SDC2, HIST1H3I, HIST2H2AB, HIST1H4B, ASCL1, ATAD5, HIST1H1D, and HIST1H2BH.

### Claim 4 (depends on 3)

The method of claim 3, wherein the panel of ER regulated genes has 87 genes, and wherein the 87 genes comprise the following 21 upregulated genes: PTPRT, CAMK1D, BCAS1, ABCG1, KRT81, TLE2, SALL4, ITGB6, BBC3, IL1R1, CORO2A, GRM4, ATP6V0A4, MATN2, PPFIBP2, BMF, LOC283070, PSCA, BAK1, PLIN2, and SYNPO; and wherein the 87 genes comprise the following 66 downregulated genes: H19, MYBL1, MGP, SLC5A8, PKIB, PGR, TMPRSS3, IGSF1, COL21A1, FSIP1, KLHL4, EGR3, NPY1R, HIST1H3C, GRIK3, SCNN1B, FRK, PRSS23, SERPINA5, SFXN2, CAP2, HIST1H2BM, CDC45, WDR62, DSCC1, GJA1, FAM196A, NTRK2, RAD54L, SDK2, SLC4A10, HIST1H4D, HIST1H4C, RGS22, SYBU, CA8, DIAPH3, FHL2, HIST1H1B, KCNH1, RAD51AP1, FANCD2, SLC39A8, SKP2, HIST1H3B, TMEM164, AURKB, DEPTOR, XRCC2, C1QTNF6, ERCC6L, ORC1, HIST2H2AC, RRM2, EME1, HIST1H2BF, CLSPN, EXO1, SDC2, HIST1H3I, HIST2H2AB, HIST1H4B, ASCL1, ATAD5, HIST1H1D, and HIST1H2BH.

### Claim 5 (depends on 3, 4)

The method of claim 3 or 4, wherein a decrease in the second ER activity score relative to the first ER activity score is predictive of on-target activity of amcenestrant.

### Claim 6 (depends on 5)

The method of claim 5, wherein the on-target activity of amcenestrant comprises ER degradation and ER inhibition.

### Claim 7 (depends on 3, 4, 5, 6)

The method of any one of claims 3-6, wherein the method comprises contacting the sample from the individual with probes.

### Claim 8 (depends on 3, 4, 5, 6, 7)

The method of any one of claims 3-7, wherein the method comprises detecting the RNA expression level of each of the N genes in the sample from the individual.

### Claim 9 (depends on 3, 4, 5, 6, 7, 8)

The method of any one of claims 3-8, wherein the method comprises RNA sequencing.

### Claim 10 (depends on 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 3-9, wherein the individual has ER+ breast cancer.

### Claim 11 (depends on 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 3-10, wherein the individual has HER2− breast cancer.

### Claim 12 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 3-11, wherein the individual has advanced or metastatic breast cancer.

### Claim 13 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 3-12, wherein the sample is a tumor biopsy.

### Claim 14 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 3-12, wherein the sample is a blood sample.

### Claim 15 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 3-12, wherein the sample is a serum sample.

### Claim 16 (depends on 13)

The method of claim 13, wherein the tumor biopsy is a formalin-fixed tumor biopsy, a paraffin-embedded tumor biopsy, a formalin-fixed paraffin-embedded (FFPE) tumor biopsy, a fresh-frozen (FF) tumor biopsy, a frozen tumor biopsy, or a fresh tumor biopsy.

### Claim 17

A kit comprising a set of probes for detecting expression of upregulated genes and downregulated genes;
wherein the upregulated genes comprise any 2 to 21 of PTPRT, CAMK1D, BCAS1, ABCG1, KRT81, TLE2, SALL4, ITGB6, BBC3, IL1R1, CORO2A, GRM4, ATP6V0A4, MATN2, PPFIBP2, BMF, LOC283070, PSCA, BAK1, PLIN2, and SYNPO; and
wherein the downregulated genes comprise any 5 to 66 of H19, MYBL1, MGP, SLC5A8, PKIB, PGR, TMPRSS3, IGSF1, COL21A1, FSIP1, KLHL4, EGR3, NPY1R, HIST1H3C, GRIK3, SCNN1B, FRK, PRSS23, SERPINA5, SFXN2, CAP2, HIST1H2BM, CDC45, WDR62, DSCC1, GJA1, FAM196A, NTRK2, RAD54L, SDK2, SLC4A10, HIST1H4D, HIST1H4C, RGS22, SYBU, CA8, DIAPH3, FHL2, HIST1H1B, KCNH1, RAD51AP1, FANCD2, SLC39A8, SKP2, HIST1H3B, TMEM164, AURKB, DEPTOR, XRCC2, C1QTNF6, ERCC6L, ORC1, HIST2H2AC, RRM2, EME1, HIST1H2BF, CLSPN, EXO1, SDC2, HIST1H3I, HIST2H2AB, HIST1H4B, ASCL1, ATAD5, HIST1H1D, and HIST1H2BH.

### Claim 18 (depends on 17)

The kit of claim 17, wherein the set of probes for detecting expression of upregulated genes and downregulated genes comprises probes to detect the upregulated genes PTPRT, CAMK1D, BCAS1, ABCG1, KRT81, TLE2, SALL4, ITGB6, BBC3, IL1R1, CORO2A, GRM4, ATP6V0A4, MATN2, PPFIBP2, BMF, LOC283070, PSCA, BAK1, PLIN2, and SYNPO; and comprises probes to detect the downregulated genes H19, MYBL1, MGP, SLC5A8, PKIB, PGR, TMPRSS3, IGSF1, COL21A1, FSIP1, KLHL4, EGR3, NPY1R, HIST1H3C, GRIK3, SCNN1B, FRK, PRSS23, SERPINA5, SFXN2, CAP2, HIST1H2BM, CDC45, WDR62, DSCC1, GJA1, FAM196A, NTRK2, RAD54L, SDK2, SLC4A10, HIST1H4D, HIST1H4C, RGS22, SYBU, CA8, DIAPH3, FHL2, HIST1H1B, KCNH1, RAD51AP1, FANCD2, SLC39A8, SKP2, HIST1H3B, TMEM164, AURKB, DEPTOR, XRCC2, C1QTNF6, ERCC6L, ORC1, HIST2H2AC, RRM2, EME1, HIST1H2BF, CLSPN, EX01, SDC2, HIST1H3I, HIST2H2AB, HIST1H4B, ASCL1, ATAD5, HIST1H1D, and HIST1H2BH.
